Loudon Investment Management LLC raised its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,630 shares of the medical research company’s stock after acquiring an additional 660 shares during the quarter. Amgen makes up about 2.3% of Loudon Investment Management LLC’s investment portfolio, making the stock its 13th biggest position. Loudon Investment Management LLC’s holdings in Amgen were worth $3,066,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. Baker Ellis Asset Management LLC purchased a new position in shares of Amgen during the third quarter valued at approximately $108,000. Phocas Financial Corp. purchased a new position in shares of Amgen during the second quarter valued at approximately $110,000. Jackson Grant Investment Advisers Inc. boosted its holdings in shares of Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 5 shares during the period. Omnia Family Wealth LLC boosted its holdings in shares of Amgen by 25.3% in the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock valued at $125,000 after purchasing an additional 147 shares during the period. Finally, Horan Capital Advisors LLC. purchased a new stake in shares of Amgen in the third quarter valued at approximately $150,000. 79.53% of the stock is currently owned by institutional investors and hedge funds.
AMGN has been the subject of a number of research reports. Argus upgraded Amgen from a “hold” rating to a “buy” rating and boosted their price target for the company from $192.33 to $220.00 in a report on Tuesday, January 23rd. Citigroup lowered Amgen to a “neutral” rating in a report on Monday, December 18th. JPMorgan Chase reissued a “hold” rating and issued a $191.00 price objective on shares of Amgen in a research note on Sunday, February 4th. Goldman Sachs downgraded shares of Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday, December 15th. Finally, Mizuho set a $192.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research note on Friday, December 22nd. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $190.57.
In related news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $185.62, for a total value of $283,070.50. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders sold a total of 4,575 shares of company stock worth $838,064 over the last ninety days. 0.19% of the stock is currently owned by corporate insiders.
NASDAQ:AMGN traded down $3.86 during mid-day trading on Friday, hitting $168.14. The company’s stock had a trading volume of 3,678,821 shares, compared to its average volume of 4,476,543. Amgen, Inc. has a 1 year low of $152.16 and a 1 year high of $201.23. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49. The firm has a market cap of $123,936.70, a price-to-earnings ratio of 13.37, a PEG ratio of 2.11 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.03 by ($0.14). Amgen had a return on equity of 30.87% and a net margin of 8.66%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.84 billion. During the same period in the previous year, the company earned $2.89 earnings per share. The company’s revenue was down 2.7% compared to the same quarter last year. equities research analysts predict that Amgen, Inc. will post 13.25 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be paid a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a yield of 3.14%. The ex-dividend date is Wednesday, May 16th. Amgen’s dividend payout ratio is presently 41.97%.
Amgen declared that its Board of Directors has authorized a share buyback plan on Thursday, February 1st that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
WARNING: “Amgen, Inc. (NASDAQ:AMGN) Shares Bought by Loudon Investment Management LLC” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/amgen-inc-amgn-holdings-raised-by-loudon-investment-management-llc.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.